NCT01018069 - AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions

Leukemia

Interventions

DRUG

AEG35156

2 hr infusion of 650 mg of AEG35156 on days 1, 2, 3 and 8. Idarubicin 12 mg/m2 over 30 minutes daily on each of days 4, 5 and 6. The dose of cytarabine will be 1.5 g/m2 daily by continuous infusion x 4 days (days 4-7) in patients under age 65 and x 3 days (days 4-6) in patients age 65 and above.

Trial Locations (18)

10595

New York Medical College, Valhalla

20246

Universitatsklinikum Hamburg-Eppendorf, Hamburg

24116

2. Medizinische Klinik und Poliklinik im Stadtischen Krankenhaus Kile GmgH, Kiel

45147

Universitatsklinimum Essen, Essen

47166

St. Johannes Hospital, Duisburg

48129

Medizinische Klinik a Hamatologie und Onkologie, Münster

55131

III. Medizinische Klinik und Poliklinik der Johannes Gutenberg-Universitat, Mainz

60611

Northwestern University Med School, div. Oncology & Hematology, Chicago

70376

Robert Boasch Krankenhaus Stuttgart, Stuttgart

76502

Cancer Research Institute of Scott & White Hospital, Temple

77303

MD Anderson Cancer Center University of Texas, Houston

80218

Rocky Mountain Blood & Marrow Transplant Program, Denver

90095

UCLA School of Medicine, Los Angeles

Unknown

Princess Margaret Hospital, Toronto

Hopital Maisonneuve-Rosemont, Montreal

Hopital Sacre Coeur, Montreal

J4V 2H1

Hopital Charles Lemoyne, Greenfield Park

09113

Klinikum Chemnitz gGmbH, Chemnitz